

A recombinant DNA clone that encodes high-affinity cell surface receptors for laminin, a glycoprotein component of basement membranes, offers an important tool for studying a variety of normal and abnormal cell processes including tumor metastases. These laminin receptors have been shown to inhibit metastases. These recombinant receptors can be used in diagnostic methods, to assess the content of laminin receptor mRNA, and to determine the pattern of laminin receptor genes in different tissue and tumor cell populations. (portfolio: Cancer—Research Materials; Cancer—Diagnostics, Mab based)

Dated: January 17, 1997.

Barbara M. McGarey,

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 97-2062 Filed 1-27-97; 8:45 am]

BILLING CODE 4140-01-M

### **National Cancer Institute; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Geographical and Statistical Modeling of Exposure to OCCs/DAHs in LI and Breast Cancer and the Environment on Long Island.

*Date:* January 31, 1997.

*Time:* 2:30 p.m.

*Place:* Teleconference, Executive Plaza North, Room 643B, 6130 Executive Boulevard, Bethesda, MD 20892.

*Contact Person:* Robert Browning, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 643B, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 20892-7405, Telephone: 301/496-7929.

*Purpose/Agenda:* To evaluate and review grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: January 21, 1997.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 97-1979 Filed 1-27-97; 8:45 am]

BILLING CODE 4140-01-M

### **National Cancer Institute; Notice of Planning Group Meeting**

Notice is hereby given that the National Cancer Institute will hold a public meeting of a Planning Group which will assist NCI in establishing a Director's Consumer Liaison Group (DCLG). The Planning Group meeting will begin at 8:30 a.m. on March 13, 1997 and will end at 1:00 p.m. on March 14, 1997 at the Holiday Inn (Bethesda, MD). All sessions of the Planning Group meeting are open to the public. However, seating is limited and will be on a first-come, first served basis.

A temporary DCLG Planning Group of NCI staff and consumer-advocates was formed to help in establishing the DCLG. The purpose of the DCLG is to: (1) Help develop and establish processes, mechanisms, and criteria for identifying appropriate consumer-advocates to serve on a variety of program and policy advisory committees responsible for advancing the mission of the NCI; (2) serve as a primary forum for discussing issues and concerns and exchanging viewpoints that are important to the broad development of NCI programmatic and research priorities, e.g., the development of the annual Bypass Budget; and (3) establish and maintain strong collaborations between NCI and the cancer advocacy community to reach common goals. The DCLG, consisting of approximately 15 consumer-advocates who are involved in cancer advocacy and/or voluntary organizations, will meet several times a year. NCI anticipates that the activities and initiatives developed by NCI, in conjunction with the DCLG, will serve as models for consumer participation. Nominations for the members of the DCLG will be solicited from the cancer advocacy community. The first meeting of the DCLG is planned for late June 1997. A notice of the date and location of this meeting will be published in the Federal Register at a later date.

The objectives of the Planning Group are to: (1) define the initial role of the DCLG; and (2) define the DCLG

membership solicitation process, as well as the criteria, categories, and rating system to identify and rank potential members of the DCLG. Development of criteria for membership on the DCLG will include identification of categories of members needed to ensure balance and diversity of representation. To identify DCLG members, the process selected by the Planning Group to announce and invite submission of names of consumer-advocates to serve on the DCLG will be followed.

Nominees will be screened for eligibility according to a set of criteria and categories developed by the DCLG Planning Group. Consumer-advocates who are on the Planning Group will be unable to serve as members of the DCLG in its first year of operation, but their organizations may be represented by another individual.

To provide input to the Planning Group, members of advocacy or voluntary organizations related to cancer are invited to submit eligibility criteria and categories that could be used to identify individuals who could serve on the DCLG. These criteria and categories will be used to help the Planning Group to develop the process for identifying DCLG members. Submissions on criteria and categories should be mailed to Ms. Fran Oscar at Palladian Partners, 7315 Wisconsin Avenue, Suite 440W, Bethesda, MD 20814, or sent to her by FAX to (301) 986-5047 or by E-mail to palladianp@aol.com. They must be received no later than 5:00 p.m. (EST) on February 15, 1997 to be included in the materials provided to the Planning Group prior to the meeting. Submissions received after that date and time will be accepted, but may not be included in the materials considered by the Planning Group members at the March 13-14 meeting. All submission must be accompanied by the following information: (1) Name and address of individual making the submission; and (2) name and address of cancer advocacy or voluntary organization with which they are affiliated.

Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other special accommodations, should call Ms. Elaine Lee, Office of Liaison Activities, NCI at (301) 496-0644 or contract her by FAX (301) 402-2594 or E-mail (lee@od.nci.nih.gov) in advance of the meeting, by February 15, 1997. For additional information, contact Ms. Lee.